Siguazodan

Pricing Availability Delivery Time Qty
Cat.No. 1148 - Siguazodan | C14H16N6O | CAS No. 115344-47-3
Description: PDE3 inhibitor
Chemical Name: N-Cyano-N'-methyl-N''-[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]guanidine
Purity: ≥99% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Phosphodiesterase inhibitor, selective for PDE3 (IC50 = 117 nM).

Compound Libraries

Siguazodan is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 284.32
Formula C14H16N6O
Storage Store at RT
Purity ≥99% (HPLC)
CAS Number 115344-47-3
PubChem ID 72124
InChI Key NUHPODZZKHQQET-UHFFFAOYSA-N
Smiles CN\C(NC#N)=N/C1=CC=C(C=C1)C1=NNC(=O)CC1C

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

SolubilitySoluble to 100 mM in DMSO

Preparing Stock Solutions

The following data is based on the product molecular weight 284.32. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.52 mL 17.59 mL 35.17 mL
5 mM 0.7 mL 3.52 mL 7.03 mL
10 mM 0.35 mL 1.76 mL 3.52 mL
50 mM 0.07 mL 0.35 mL 0.7 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Freitag et al (1998) Phosphodiesterase inhibitors suppress α2-adrenoceptor-mediated 5-hydroxytryptamine release from trachea of newborn rabbits. Eur.J.Pharmacol. 354 67 PMID: 9726632

Tang et al (1994) Photoaffinity labelling of cyclic GMP-inhibited phosphodiesterase (PDE III) in human and rat platelets and rat tissues: effects of phosphodiesterase inhibitors. Eur.J.Pharmacol. 268 105 PMID: 7925608

Christensen and Torphy (1994) Isozyme-selective phosphodiesterase inhibitors as antiasthmatic agents. Annu.Rep.Med.Chem. 29 185 PMID:


If you know of a relevant reference for Siguazodan, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: Siguazodan, supplier, PDE3, inhibitors, inhibits, Phosphodiesterases, Phosphodiesterases, Phosphodiesterases, Tocris Bioscience

Citations for Siguazodan

Citations are publications that use Tocris products.

Currently there are no citations for Siguazodan. Do you know of a great paper that uses Siguazodan from Tocris? If so please let us know.

Siguazodan Reviews

Average Rating:

(Based on 0 Reviews)


1 Star
0%
2 Star
0%
3 Star
0%
4 Star
0%
5 Star
0%

Have you used Siguazodan?

Submit a review and receive a $25US/€18/£15/$25CAN Amazon gift card if you include an image -$10US/€7/£6/$10CAN Amazon gift card for reviews without an image. Limited to verified customers in USA, Canada and Europe.


Literature in this Area

Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.